

Commercial/Healthcare Exchange PA Criteria

Effective: August 2016

Prior Authorization: Cotellic

Products Affected: Cotellic (cobimetinib) oral tablet

Medication Description:

Cotellic is a mitogen-activated extracellular signal regulated kinase (MEK) inhibitor indicated in combination with Zelboraf® (vemurafenib tablets), for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutation. It is not indicated for use in patients with wild-type BRAF melanoma. Some mutations in the BRAF gene can result in constitutively activated BRAF kinases that may stimulate tumor cell growth.¹ Cotellic is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/MEK1 and MEK2.1 Cotellic and Zelboraf (a BRAF inhibitor) target two different kinases; compared with either drug alone, coadministration resulted in increased apoptosis in vitro and in animal models.

Covered Uses: Treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Presence of BRAF V600E or V600K mutation

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with, an Oncologist.

Coverage Duration: 3 years

Other Criteria:

- A. Patient has a diagnosis of unresectable or metastatic melanoma; **AND**
- B. Patient has a BRAF V600E or V600K mutation; **AND**
- C. Patient will be using Cotellic in combination with vemurafenib.

References:

1. Cotellic. [package insert]. San Francisco, CA: Genentech Inc.; November 2015.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	8/2016
2	Update	Removed from CCI Oncology policy and adopted EmblemHealth (parent company) Cotellic PA Policy	All	8/4/2020